CAS 1809336-93-3

Valemetostat tosylate

CAS : 1809336-93-3

Formule : C₃₃H₄₂ClN₃O₇S

Degré de pureté : 98%

Masse moléculaire : 660.2205

Ref: IN-DA01V4EN

(R)-7-Chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxamide 4-methylbenzenesulfonate

CAS : 1809336-93-3

(R)-7-Chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethylbenzo[d][1,3]dioxole-5-carboxamide 4-methylbenzenesulfonate

Degré de pureté : 98%

Masse moléculaire : 660.23g/mol

Ref: 54-OR1074780

Valemetostat tosylate

CAS : 1809336-93-3

Valemetostat is a histone methyltransferase inhibitor that inhibits the catalytic activity of lysine methyltransferases, which are enzymes that add methyl groups to histones. Valemetostat has been shown to be an antineoplastic agent in stem-cell cultures and animal models, although its mechanism of action is not yet elucidated. Valemetostat is currently being studied as a treatment for cancer in humans.
Valemetostat inhibits the transcriptional activation by binding to the histones H3 and H4, preventing them from binding to DNA. This prevents transcription and synthesis of proteins that regulate cellular function, leading to cell death.

Formule : C₃₃H₄₂ClN₃O₇S

Degré de pureté : Min. 95%

Masse moléculaire : 660.2 g/mol

Ref: 3D-JXC33693

Valemetostat tosylate

CAS : 1809336-93-3

Valemetostat tosylate is a dual inhibitor of EZH1/2 and used in the research of relapsed/refractory peripheral T-cell lymphoma.

Formule : C₃₃H₄₂ClN₃O₇S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 660.22

Ref: TM-T13279